Cognition (CGTX) Q2 Grant Income Jumps

Cognition Therapeutics (NASDAQ:CGTX), a clinical-stage biotechnology firm focused on developing therapies for neurodegenerative diseases, released its earnings for Q2 2025 on August 7, 2025. The company reported a GAAP net loss per share of $(0.11) for Q2 2025, missing consensus estimates by $(0.005)The company reported a net loss per share of $(0.11) for the quarter ended June 30, 2025, compared to $(0.18) in the prior year period.GAAP grant income stood at $7.1 million for Q2 2025, outperforming analyst expectations of no recognized GAAP revenue. Total cash, cash equivalents, and restricted cash equivalents declined to $11.6 million as of Q2 2025. The quarter reflected modest financial progress, operational discipline in cutting administrative expenses, and notable clinical milestones despite persistent operating losses and continued reliance on grant funding.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool